Cargando…

(18)F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals

Background. Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernard-Gauthier, Vadim, Wängler, Carmen, Schirrmacher, Esther, Kostikov, Alexey, Jurkschat, Klaus, Wängler, Bjoern, Schirrmacher, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135131/ https://www.ncbi.nlm.nih.gov/pubmed/25157357 http://dx.doi.org/10.1155/2014/454503

Ejemplares similares

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) (18)F-Radiopharmaceuticals
por: Gower-Fry, Lexi, et al.
Publicado: (2021)

Good practices for the automated production of (18)F-SiFA radiopharmaceuticals
por: Blok, Simon, et al.
Publicado: (2023)

t-Bu(2)SiF-Derivatized D(2)-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging
por: Iovkova-Berends, Ljuba, et al.
Publicado: (2011)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
por: Schirrmacher, Ralf, et al.
Publicado: (2019)

iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with (68)Ga and (64)Cu: Unexpected Findings
por: Litau, Shanna, et al.
Publicado: (2018)

Synthesis of a Bifunctional Cross‐Bridged Chelating Agent, Peptide Conjugation, and Comparison of (68)Ga Labeling and Complex Stability Characteristics with Established Chelators
por: Damerow, Helen, et al.
Publicado: (2022)

Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development
por: Seibold, Uwe, et al.
Publicado: (2014)

Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)

(89)Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
por: Fischer, Gabriel, et al.
Publicado: (2013)

Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
por: Judmann, Benedikt, et al.
Publicado: (2023)

Side-by-Side Comparison of Five Chelators for (89)Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
por: Damerow, Helen, et al.
Publicado: (2021)

Dosimetry of [(18)F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans
por: Thiel, Alexander, et al.
Publicado: (2023)

Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
por: Judmann, Benedikt, et al.
Publicado: (2020)

Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors
por: Judmann, Benedikt, et al.
Publicado: (2022)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Synthesis, Radiolabeling, and In Vitro and In Vivo Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin α(v)β(3) Targeting
por: Braun, Diana, et al.
Publicado: (2023)

Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y(1))- and GRP-Receptors—An Improvement for Breast Cancer Imaging?
por: Vall-Sagarra, Alicia, et al.
Publicado: (2018)

Hybrid Multimodal Imaging Synthons for Chemoselective and Efficient Biomolecule Modification with Chelator and Near-Infrared Fluorescent Cyanine Dye
por: Hübner, Ralph, et al.
Publicado: (2020)

Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α(v)β(3) and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?
por: Cheng, Xia, et al.
Publicado: (2021)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

α(v)β(3)-Specific Gold Nanoparticles for Fluorescence Imaging of Tumor Angiogenesis
por: Pretze, Marc, et al.
Publicado: (2021)

PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study †
por: Hübner, Ralph, et al.
Publicado: (2021)

Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2015)

Cholinergic Depletion in Alzheimer's Disease Shown by [(18)F]FEOBV Autoradiography
por: Parent, Maxime J., et al.
Publicado: (2013)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Functional Hybrid Molecules for the Visualization of Cancer: PESIN‐Homodimers Combined with Multimodal Molecular Imaging Probes for Positron Emission Tomography and Optical Imaging: Suited for Tracking of GRPR‐Positive Malignant Tissue
por: Hübner, Ralph, et al.
Publicado: (2020)

Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [(18)F]FEOBV and choline acetyltransferase immunochemistry
por: Parent, Maxime J, et al.
Publicado: (2013)

GMP-compliant production of [(68)Ga]Ga-NeoB for positron emission tomography imaging of patients with gastrointestinal stromal tumor
por: Pretze, Marc, et al.
Publicado: (2021)

A first-in-human study of [(68)Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death
por: Ho Shon, Ivan, et al.
Publicado: (2022)

[(18)F]Tosyl fluoride as a versatile [(18)F]fluoride source for the preparation of (18)F-labeled radiopharmaceuticals
por: Zhou, Dong, et al.
Publicado: (2023)

GABA(A) receptors in visual and auditory cortex and neural activity changes during basic visual stimulation
por: Qin, Pengmin, et al.
Publicado: (2012)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors
por: Jung, Ji-hoon, et al.
Publicado: (2018)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer
por: Sakulpisuti, Chaninart, et al.
Publicado: (2022)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Quality control of positron emission tomography radiopharmaceuticals: An institutional experience
por: Shukla, Jaya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lujucd1v77ms6igqfi129rfvb7